 Shanghai Junshi Biosciences Co Ltd and Coherus BioSciences Inc NASDAQ: CHRS have announced positive results from the pivotal Phase 3 JUPITER-02 trial evaluating toripalimab plus chemotherapy for the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma NPC. The results will be presented at the annual meeting of the American Society for Clinical Oncology. 